RPL17 and colorectal carcinoma: However, in contrast to PD‐1 blockade in patients with dMMR/MSI‐H CRC, the achievement of pCR and MPR in patients with pMMR/MSS CRC was not associated with increased TMB or pathogenic mutations (Figure S7).